Mobia Medical IPO: developer of stroke rehabilitation systems goes public

Preliminary trading in shares of Mobia Medical, a manufacturer of medical devices for rehabilitation of patients after stroke, has started in the trading system for Freedom clients. The company's flagship solution is the Vivistim system, an implantable vagus nerve stimulation device that helps chronic ischemic stroke patients regain motor function through neuroplasticity in the brain. Later on Ma. 8, Mobia Medical's securities will appear on the Nasdaq under the ticker MOBI.

Mobia Medical successfully raised $150 million in an IPO. It placed 10 million shares at $15 - exactly in the middle of the announced price range. Based on the IPO results, the value of the entire company can be estimated at $549 mln, Renaissance Capital points out.

The listing was organized by BofA Securities, JPMorgan, Goldman Sachs, BTIG and Wolfe Nomura Alliance.

Prior to the IPO, Mobia's shareholders included venture capital funds such as U.S. Venture Partners, GPG Healthcare Opportunities, Osage University Partners, Synapse Investment, Gilde Healthcare and Longitude Venture Partners, according to the company's prospectus filed with the U.S. Securities and Exchange Commission (SEC).

The company plans to use the proceeds from the offering to expand its direct sales and commercial service, continue research and clinical trials, and for working capital, the document said.

Austin-based Mobia Medical was founded in 2007 under the name MicroTransponder, a name it didn't change until early 2026. Its flagship product is Vivistim, the world's first "paired stimulation" system that uses electrical impulses to force the brain to create new connections to restore mobility in the arms, hands and forearms after a stroke, according to the company's website. The technology is 2-3 times more effective than conventional exercise and produces results even years after the illness, the website claims. Essentially, the device helps the brain re-learn how to control the body, giving patients back the ability to handle everyday activities. In 2021, Vivistim received approval from the relevant regulator.

Since its full commercial launch in 2023, the system has been implanted in more than 1,000 patients, with 70% of the total implanted last year, Seeking Alpha notes.

The global market for neurostimulation devices was estimated at $5.8 billion in 2024 and is expected to exceed $13.9 billion by 2033, according to Donovan Jones, an expert at IPO Edge, an analytical company. Thus, the average annual growth rate may reach 10.3%.

According to Mobia's SEC filing, its revenue increased 105% to $32 million in 2025, with gross margin reaching 81%. However, the company's net loss grew 90% to $46.5 million over the same period.

Mobia's main advantage, according to Donovan Jones, is that it was the first to bring the technology to market, creating the only regulator-approved device in its segment. This has provided the company with the ability to scale its operating model through specialized medical centers. However, it faces serious risks: the main challenges are related to reimbursement, as most insurers still consider the product experimental. In addition, the business is extremely dependent on a single device and incurs high costs that require ongoing investment, Jones emphasizes.

Mobia had $33.6 million in cash at the end of 2025, but it issued $40 million in convertible promissory notes as early as early 2026, the expert adds. This signals that due to the high rate of cash burn, the company urgently needed funds, which it probably could not get from existing investors without changing its valuation. Without the influx of funds from the IPO, the company's cash reserves would have been sufficient to sustain operations for less than a year, the analyst believes.

Freedom Finance analyst Alem Bektemirov estimates that the target for Mobia's securities is $21.1, which implies a potential growth of quotations by 40.7% relative to the offering level. The expert also considers the full dependence of the business on sales of a single product, failure in promotion of which will deprive the company of its livelihood. In addition, Mobia is critically dependent on a narrow circle of exclusive suppliers, and any failure in their work can completely stop production, the analyst warned.

___________________

Freedom clients will be able to get access to Mobia Medical shares before the opening of the main exchange session. Trading will begin in the early pre-market format 2-3 hours before the opening of the U.S. exchanges (from 15:30-16:30 Astana time). To participate, click on MOBI ticker.

This article was AI-translated and verified by a human editor